 Home > Active Ingredient News > Antitumor Therapy > J Urol: The benefits of neoadjuvant chemotherapy before cystectomy on the pathological staging and survival prognosis of muscle-invasive bladder cancer

J Urol: The benefits of neoadjuvant chemotherapy before cystectomy on the pathological staging and survival prognosis of muscle-invasive bladder cancer

 Last Update: 2021-06-01
 Source: Internet
 Author: User

Tags

3 8 7 16

etiology cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bladder cancer is the 4th most common cancer in men, and the 6th incidence among all populations, accounting for 4.

The purpose of this study was to evaluate the association between neoadjuvant chemotherapy and decreased pathological stage and OS in patients with MIBC with histological variants.

Researchers screened MIBC patients without metastasis who underwent radical cystectomy from 2004 to 2017 from the National Cancer Database .

Screening

The final study population included 31,218 patients: urothelial carcinoma (UC): 27779 cases; sarcomatoid UC: 501 cases; micropapillary UC: 418 cases; squamous cell carcinoma (SCC): 1141 cases; neuroendocrine carcinoma: 629 cases; adenocarcinoma: 750 cases.

Down-regulation of pathological staging in patients with or without neoadjuvant chemotherapy

In all histological subgroups, neoadjuvant chemotherapy was associated with pathological staging down-regulation to pT0N0 (odds ratio of UC [OR]: 5.

In all histological subgroups, neoadjuvant chemotherapy is associated with down-regulation of pathological staging to pT0N0

Neoadjuvant chemotherapy is associated with improvement in OS in patients with UC (HR 0.

Neoadjuvant chemotherapy is associated with improvement of OS in patients with UC sarcomatoid UC and neuroendocrine cancer .

Neoadjuvant chemotherapy is associated with the down-regulation of the pathological staging of MIBC of all histological variants, as well as the improvement of OS in patients with UC, sarcomatoid UC, and neuroendocrine carcinoma

Original source:

Chakiryan Nicholas H, Jiang Da David, Gillis Kyle A et al.

org/10.
1097/JU.
0000000000001855" target="_blank" rel="noopener">Pathologic Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.